1 thought on “Strategic analysis of North China Pharmaceutical”

  1. To put it in recent years, the high -quality tracks that have been produced by cattle stocks in recent years will count the pharmaceutical industry. If we use 10 years as a period, it is not difficult to see that companies with more than 10 times have abound. There are also many enterprises, but compared to other industries, the industry chain is long, the differences between the industry are large, and the pharmaceutical industry that is affected by policies will become less simple and easy. Therefore, our main content today is one of the largest pharmaceutical companies in China-North China Pharmaceutical. Is it worth investing in? Let’s talk together.

    For North China Pharmaceutical, before starting analysis, the list of leading stocks in the pharmaceutical industry will be shared with you. Click on a limited time to receive: Treasure Information: The list of leaders in the pharmaceutical industry
    n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n R n. From the perspective of the company

    In company introduction: North China Pharmaceutical is one of the earliest pharmaceutical companies in the field of biopharmaceuticals in China. The company also has other projects. The company adopts an industrial chain integrated business operation model, which contains the research and development, production and sales of pharmaceutical products. The scope of the product is chemicals, biopharmaceuticals, healthy consumer goods, etc. In addition to cardiovascular and cerebrovascular drugs, the treatment fields involved in the company are very extensive, as well as more than 700 product regulations such as kidney disease and immune regulatory drugs. Not bad.

    Is we understand the basic situation of this company, and then look at what flash points this old pharmaceutical company has.

    In highlights: combined with hard and hard, integrates brand and technology in one

    for the company to engage in pharmaceutical manufacturing for more than 60 years. Zhihe’s good reputation. By the end of 2020, the company has won two well -known trademarks in North China, Eno, and more than 20 well -known trademarks such as Qingdi, Qianglintan, and Zhishu. Promotion and sales have shaped a strong foundation.

    It, the company attaches great importance to research and development innovation in research technology. It is the first batch of national technology centers for corporate technology centers and national engineering research centers of microbiopathic drugs. At the same time, it has the largest pharmaceutical microbial fungus resource library in the domestic pharmaceutical industry, and the largest domestic microbial new drug filtering of bacteria library and metabolic product library. New drug screening for microorganisms is at the leading level in China.

    In highlights: stronger, constantly seeking upwards

    The company in the field of antibiotics is a highlight, production scale, technical level, and product quality in the industry in the industry It is relatively advanced, but the company is not satisfied with this, but has vigorously reformed and innovated marketing through this foundation, so that the integration of marketing resources of preparations and drugs has been accelerated, the level of business management is improved. Expansion and vigorously develop the international market. With the combination of brand, technology, marketing, and channels, the company will play a huge role of 1 1 1 1> 4, so that the company’s future development will have a more solid foundation.

    of course, the company’s multiple powerful advantages are also reflected in many aspects of management, products, quality, etc. The length should not be too long. Other in -depth reports and risk reminders related to North China Pharmaceuticals. In the report, click to browse immediately: [Deep Research] North China Pharmaceutical Comment, it is recommended to collect it!

    . From the perspective of the industry

    The sisters told you at the beginning that the pharmaceutical industry is an industry that often appears in bull stocks. There are such grand occasions. With the intensification of domestic aging, the development of domestic innovative drugs has continued to accelerate. The upward space of the pharmaceutical industry in the short time is wide.

    . Unfortunately, there is still a clear problem in the industry, because the impact of policy changes, for example, in order to reduce medical insurance expenses, alleviate the burden on the masses, implement large -scale collective mining, allow pharmaceutical companies’ prices to prices To become low, to force the profit of pharmaceutical companies. In the future, there are no new policies to disturb the profit rhythm of pharmaceutical companies, everything is unknown. The risks faced by enterprises are also unpredictable. On August 20, 2021, North China Pharmaceutical was interrupted for a certain episode of drugs, so it limited its collection of collection in the next nine months. The company’s stock price ushered in a limit on August 23, 2021.

    So in the pharmaceutical industry with endless policy changes, I want to understand the future market of North China Pharmaceutical, directly open the link below. Good timing of buying or selling: [Free] Is there a chance to test the North China Pharmaceutical?

    The Answee time: 2021-09-07, the latest business changes are based on the data displayed in the link in the text, please click to view

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Scroll to Top